Predicting translational progress in biomedical research.


Journal

PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755

Informations de publication

Date de publication:
10 2019
Historique:
received: 29 11 2018
accepted: 06 09 2019
entrez: 11 10 2019
pubmed: 11 10 2019
medline: 26 2 2020
Statut: epublish

Résumé

Fundamental scientific advances can take decades to translate into improvements in human health. Shortening this interval would increase the rate at which scientific discoveries lead to successful treatment of human disease. One way to accomplish this would be to identify which advances in knowledge are most likely to translate into clinical research. Toward that end, we built a machine learning system that detects whether a paper is likely to be cited by a future clinical trial or guideline. Despite the noisiness of citation dynamics, as little as 2 years of postpublication data yield accurate predictions about a paper's eventual citation by a clinical article (accuracy = 84%, F1 score = 0.56; compared to 19% accuracy by chance). We found that distinct knowledge flow trajectories are linked to papers that either succeed or fail to influence clinical research. Translational progress in biomedicine can therefore be assessed and predicted in real time based on information conveyed by the scientific community's early reaction to a paper.

Identifiants

pubmed: 31600189
doi: 10.1371/journal.pbio.3000416
pii: PBIOLOGY-D-18-01383
pmc: PMC6786525
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3000416

Subventions

Organisme : Intramural NIH HHS
ID : Z99 OD999999
Pays : United States

Déclaration de conflit d'intérêts

Since the authors work in the Division of Program Coordination, Planning, and Strategic Initiatives at the National Institutes of Health, our work could have policy implications for how research portfolios are evaluated.

Références

Clin Ther. 2017 Jul;39(7):1409-1425.e20
pubmed: 28652015
Front Comput Neurosci. 2012 Mar 05;6:8
pubmed: 22403538
PLoS One. 2008 Jul 23;3(7):e2778
pubmed: 18648663
JAMA Psychiatry. 2017 Jan 1;74(1):5-6
pubmed: 27784040
J Transl Med. 2013 May 24;11:126
pubmed: 23705970
J Am Med Inform Assoc. 2019 Jun 1;26(6):516-523
pubmed: 30830170
PLoS One. 2017 May 8;12(5):e0177371
pubmed: 28481922
Brief Bioinform. 2018 Nov 27;19(6):1400-1414
pubmed: 28633401
Health Res Policy Syst. 2016 Aug 09;14(1):60
pubmed: 27507300
Clin Transl Sci. 2011 Jun;4(3):153-62
pubmed: 21707944
Health Res Policy Syst. 2015 Jan 01;13:1
pubmed: 25552353
JAMA. 2014 Aug 6;312(5):483-4
pubmed: 24911291
Science. 2013 Oct 4;342(6154):127-32
pubmed: 24092745
PLoS Biol. 2019 Oct 10;17(10):e3000385
pubmed: 31600197
Clin Ther. 2015 Aug;37(8):1643-51.e3
pubmed: 26243074
Cell. 2015 Sep 24;163(1):21-3
pubmed: 26406364
Neural Comput. 2006 Jul;18(7):1527-54
pubmed: 16764513
PLoS Biol. 2016 Sep 06;14(9):e1002541
pubmed: 27599104
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
PLoS One. 2017 Mar 27;12(3):e0174538
pubmed: 28346525
Proc Natl Acad Sci U S A. 1920 Jun;6(6):275-88
pubmed: 16576496
Wiley Interdiscip Rev Data Min Knowl Discov. 2011 Jan;1(1):55-63
pubmed: 22523608
Mol Biol Cell. 2013 May;24(10):1505-6
pubmed: 23686606
J Transl Med. 2016 Aug 05;14(1):235
pubmed: 27492440
Mol Biol Cell. 2017 Jun 1;28(11):1401-1408
pubmed: 28559438
Sleep Med Rev. 2018 Aug;40:109-126
pubmed: 29248294
Sci Transl Med. 2018 Apr 25;10(438):
pubmed: 29695453
Science. 2008 Sep 5;321(5894):1298-9
pubmed: 18772421
Nat Genet. 2015 Aug;47(8):856-60
pubmed: 26121088
J Pain Palliat Care Pharmacother. 2008;22(1):45-46
pubmed: 28792816
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2329-2334
pubmed: 29440428
Neuropsychopharmacology. 2014 Jan;39(1):230-2
pubmed: 24317308

Auteurs

B Ian Hutchins (BI)

Office of Portfolio Analysis, Division of Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health, Bethesda, Maryland, United States of America.

Matthew T Davis (MT)

Office of Portfolio Analysis, Division of Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health, Bethesda, Maryland, United States of America.

Rebecca A Meseroll (RA)

Office of Portfolio Analysis, Division of Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health, Bethesda, Maryland, United States of America.

George M Santangelo (GM)

Office of Portfolio Analysis, Division of Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health, Bethesda, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH